Published in Am J Respir Crit Care Med on October 04, 2007
Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA (2008) 6.24
Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax (2013) 3.62
Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res (2009) 2.31
Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med (2011) 2.30
Macrolide antibiotics for prevention of chronic obstructive pulmonary disease exacerbations: are we there yet? Am J Respir Crit Care Med (2014) 2.00
Exacerbation rate, health status and mortality in COPD--a review of potential interventions. Int J Chron Obstruct Pulmon Dis (2009) 1.85
Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med (2009) 1.70
Influence of anxiety on health outcomes in COPD. Thorax (2010) 1.52
Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis (2010) 1.51
Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physicians. Int J Chron Obstruct Pulmon Dis (2011) 1.51
COPD in primary care: a time of opportunity. Br J Gen Pract (2010) 1.44
Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a multicenter cohort study. Mayo Clin Proc (2014) 1.42
Validity of chronic obstructive pulmonary disease diagnoses in a large administrative database. Can Respir J (2012) 1.39
Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med (2009) 1.37
The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res (2013) 1.37
Tiotropium HandiHaler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis (2009) 1.32
Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. BMC Med (2011) 1.25
The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J (2012) 1.23
Do symptoms predict COPD in smokers? Chest (2010) 1.22
Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin Epidemiol (2011) 1.21
Overtreatment of COPD with inhaled corticosteroids--implications for safety and costs: cross-sectional observational study. PLoS One (2013) 1.18
Informing clinical practice guideline development and implementation: prevalence of coexisting conditions among adults with coronary heart disease. J Am Geriatr Soc (2011) 1.15
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res (2010) 1.14
Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations. Lung India (2013) 1.13
Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial. BMJ Open (2012) 1.13
The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. Dtsch Arztebl Int (2016) 1.12
Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet (2015) 1.11
New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. Br J Clin Pharmacol (2015) 1.10
Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respir Res (2011) 1.08
Risk factors for pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan: a nationwide cohort study. BMC Infect Dis (2013) 1.05
Optimizing management of chronic obstructive pulmonary disease in the upcoming decade. Int J Chron Obstruct Pulmon Dis (2011) 1.05
Virus-induced exacerbations in asthma and COPD. Front Microbiol (2013) 1.04
Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis (2015) 1.03
LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis (2015) 1.02
Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review. BMC Med (2009) 1.02
Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis (2013) 1.01
Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis. Int J Chron Obstruct Pulmon Dis (2015) 0.99
Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax (2015) 0.98
Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella pneumoniae in mice. Respir Res (2012) 0.98
Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines. Basic Clin Pharmacol Toxicol (2015) 0.97
COPD: what is the unmet need? Br J Pharmacol (2008) 0.95
The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2013) 0.95
Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis. BMC Pulm Med (2010) 0.95
Patient characteristics, treatment patterns, and health outcomes among COPD phenotypes. Int J Chron Obstruct Pulmon Dis (2012) 0.94
Improvement of Airflow Limitation by Fluticasone Propionate/Salmeterol in Chronic Obstructive Pulmonary Disease: What is the Specific Marker? Front Pharmacol (2011) 0.94
A new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPD. BMJ Open (2012) 0.93
A bibliometric analysis of the 100 most influential papers on COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.90
Ten years of tiotropium: clinical impact and patient perspectives. Int J Chron Obstruct Pulmon Dis (2013) 0.89
Prescription practices for chronic obstructive pulmonary disease: findings from the national ambulatory medical care survey 1999-2010. COPD (2014) 0.89
Maternal smoking promotes chronic obstructive lung disease in the offspring as adults. Eur J Med Res (2009) 0.89
One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res (2008) 0.89
Safety, tolerability and risk benefit analysis of tiotropium in COPD. Int J Chron Obstruct Pulmon Dis (2008) 0.89
Chronic obstructive pulmonary disease hospital admissions and drugs--unexpected positive associations: a retrospective general practice cohort study. NPJ Prim Care Respir Med (2014) 0.88
Optimising treatment for COPD--new strategies for combination therapy. Int J Clin Pract (2009) 0.87
Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2010) 0.87
Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort. BMC Pulm Med (2016) 0.86
Inhaled Corticosteroids Increase the Risk of Pneumonia in Patients With Chronic Obstructive Pulmonary Disease: A Nationwide Cohort Study. Medicine (Baltimore) (2015) 0.86
Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations. Clin Med Insights Circ Respir Pulm Med (2011) 0.86
Can the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting? Drug Des Devel Ther (2013) 0.86
Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies. Int J Chron Obstruct Pulmon Dis (2009) 0.86
The Role of Bronchodilators in Preventing Exacerbations of Chronic Obstructive Pulmonary Disease. Tuberc Respir Dis (Seoul) (2016) 0.85
A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD. Int J Chron Obstruct Pulmon Dis (2009) 0.85
Targeted treatment in COPD: a multi-system approach for a multi-system disease. Int J Chron Obstruct Pulmon Dis (2009) 0.85
The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD. Int J Chron Obstruct Pulmon Dis (2010) 0.85
Characteristics of Dutch and Swiss primary care COPD patients - baseline data of the ICE COLD ERIC study. Clin Epidemiol (2011) 0.85
Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective. Br J Clin Pharmacol (2014) 0.84
Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int J Chron Obstruct Pulmon Dis (2009) 0.84
Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic obstructive pulmonary disease. Lung (2012) 0.84
The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease. Respir Res (2010) 0.84
Long-term therapy in COPD: any evidence of adverse effect on bone? Int J Chron Obstruct Pulmon Dis (2009) 0.83
Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities. Ther Adv Chronic Dis (2010) 0.83
Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study. Int J Chron Obstruct Pulmon Dis (2014) 0.82
Influencing the decline of lung function in COPD: use of pharmacotherapy. Int J Chron Obstruct Pulmon Dis (2010) 0.82
Relationship between the use of inhaled steroids for chronic respiratory diseases and early outcomes in community-acquired pneumonia. PLoS One (2013) 0.82
Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan. Int J Chron Obstruct Pulmon Dis (2015) 0.82
Tiotropium bromide: an update. Open Respir Med J (2009) 0.82
The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis. Respir Res (2016) 0.82
Elevated placenta growth factor predicts pneumonia in patients with chronic obstructive pulmonary disease under inhaled corticosteroids therapy. BMC Pulm Med (2011) 0.81
A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study. Int J Chron Obstruct Pulmon Dis (2015) 0.81
A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother (2015) 0.81
Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial Asthma. J Clin Med Res (2015) 0.81
Heart failure and chronic obstructive pulmonary disease: Two for tea or tea for two? World J Cardiol (2010) 0.81
Length of stay of COPD hospital admissions between 2006 and 2010: a retrospective longitudinal study. Int J Chron Obstruct Pulmon Dis (2015) 0.80
Are COPD patients with pneumonia who are taking inhaled corticosteroids at higher risk of dying? Eur Respir J (2011) 0.80
Inhaled Corticosteroids. Pharmaceuticals (Basel) (2010) 0.79
LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. Int J Chron Obstruct Pulmon Dis (2015) 0.79
Smoking cessation for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser (2012) 0.79
Is 'GOLD' standard for the management of COPD in clinical practice? Drugs Context (2012) 0.79
The INSPIRE study: influence of prior use and discontinuation of inhaled corticosteroids. Am J Respir Crit Care Med (2008) 0.79
Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD. Ther Clin Risk Manag (2015) 0.79
Assessment of health status in patients with newly diagnosed chronic obstructive pulmonary disease. PLoS One (2013) 0.79
Pharmacotherapies for COPD. Clin Med Insights Circ Respir Pulm Med (2013) 0.79
Glucocorticoid-Augmented Efferocytosis Inhibits Pulmonary Pneumococcal Clearance in Mice by Reducing Alveolar Macrophage Bactericidal Function. J Immunol (2015) 0.79
Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease-The Shifting Treatment Paradigm. COPD (2015) 0.78
Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA. Int J Chron Obstruct Pulmon Dis (2016) 0.78
The Effect of Amlodipine and Sildenafil on the NT-ProBNP Level of Patients with COPD-Induced Pulmonary Hypertension. Iran J Pharm Res (2014) 0.78
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med (2014) 6.29
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med (2008) 6.17
Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med (2011) 5.69
Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res (2010) 5.17
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet (2009) 4.40
Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet (2009) 3.93
Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J (2004) 3.77
Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 3.70
Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med (2012) 3.44
Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One (2012) 2.52
Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest (2013) 2.42
Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD (2009) 2.41
Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res (2009) 2.31
Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest (2009) 2.20
An initial strategy of intensive medical therapy is comparable to that of coronary revascularization for suppression of scintigraphic ischemia in high-risk but stable survivors of acute myocardial infarction. J Am Coll Cardiol (2006) 2.16
The GOLD classification has advanced understanding of COPD. Am J Respir Crit Care Med (2004) 2.00
A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet (2011) 1.98
Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med (2007) 1.88
Systemic inflammation and comorbidity in COPD: a result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence. Thorax (2010) 1.82
Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence. Blood (2013) 1.73
Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc (2015) 1.72
Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J (2013) 1.66
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
Wnt signalling in lung development and diseases. Respir Res (2006) 1.55
Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respir Med (2005) 1.54
Assessment of pulmonary neutrophilic inflammation in emphysema by quantitative positron emission tomography. Am J Respir Crit Care Med (2012) 1.53
Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. Respir Res (2011) 1.52
Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity--a common inflammatory phenotype? Respir Res (2006) 1.51
The Association Between Heroin Inhalation and Early Onset Emphysema. Chest (2015) 1.46
Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med (2004) 1.43
Outdoor air pollution and respiratory health in patients with COPD. Thorax (2011) 1.42
Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med (2013) 1.41
Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. Am J Respir Crit Care Med (2010) 1.33
Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. Respir Med (2013) 1.31
Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med (2010) 1.30
Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc (2011) 1.28
Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med (2011) 1.23
Progression parameters for emphysema: a clinical investigation. Respir Med (2007) 1.22
Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med (2014) 1.20
Variability in densitometric assessment of pulmonary emphysema with computed tomography. Invest Radiol (2005) 1.19
The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD). Prim Care Respir J (2007) 1.16
Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2005) 1.16
Tuberculosis and its incidence, special nature, and relationship with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2007) 1.14
Chronic obstructive pulmonary disease and exacerbations: patient insights from the global Hidden Depths of COPD survey. BMC Pulm Med (2013) 1.14
Number needed to treat in COPD: exacerbations versus pneumonias. Thorax (2013) 1.12
Influence of calibration on densitometric studies of emphysema progression using computed tomography. Am J Respir Crit Care Med (2004) 1.11
A multinational study to establish the value of early adenosine technetium-99m sestamibi myocardial perfusion imaging in identifying a low-risk group for early hospital discharge after acute myocardial infarction. J Am Coll Cardiol (2006) 1.11
Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. Respir Med (2011) 1.11
Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD. J Clin Immunol (2009) 1.10
Factors associated with change in exacerbation frequency in COPD. Respir Res (2013) 1.08
Psychiatric disorder and quality of life in patients awaiting lung transplantation. Chest (2003) 1.07
Inflammation in sputum relates to progression of disease in subjects with COPD: a prospective descriptive study. Respir Res (2006) 1.05
COPD performance measures: missing opportunities for improving care. Chest (2010) 1.05
Baseline 6-min walk distance predicts survival in lung transplant candidates. Am J Transplant (2008) 1.04
The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Eur Respir J (2012) 1.03
Gas exchange and exercise capacity affect neurocognitive performance in patients with lung disease. Psychosom Med (2005) 1.03
α₁-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. Chest (2010) 1.02
Early donor management increases the retrieval rate of lungs for transplantation. Ann Thorac Surg (2008) 1.01
Radiologic and clinical features of COPD patients with discordant pulmonary physiology: lessons from alpha1-antitrypsin deficiency. Chest (2007) 0.99
The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease. COPD (2008) 0.99
A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest (2002) 0.98
IgA1 protease. Int J Biochem Cell Biol (2005) 0.95
The genetics of chronic obstructive pulmonary disease. Respir Res (2006) 0.95
Investigating new standards for prophylaxis in reduction of exacerbations--the INSPIRE study methodology. COPD (2007) 0.95
Alpha-1-antitrypsin replacement therapy: current status. Curr Opin Pulm Med (2006) 0.95
Detection of emphysema progression in alpha 1-antitrypsin deficiency using CT densitometry; methodological advances. Respir Res (2008) 0.93
Comorbid disease in asthma: the importance of diagnosis. Expert Rev Respir Med (2010) 0.93
Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. BMC Pulm Med (2014) 0.93
Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2011) 0.92
The TNFalpha gene relates to clinical phenotype in alpha-1-antitrypsin deficiency. Respir Res (2008) 0.92
Comparison of the sensitivities of 5 different computed tomography scanners for the assessment of the progression of pulmonary emphysema: a phantom study. Invest Radiol (2004) 0.92
The effect of continuous positive airway pressure usage on sleepiness in obstructive sleep apnoea: real effects or expectation of benefit? Thorax (2012) 0.91
Changes in body composition in patients with chronic obstructive pulmonary disease: do they influence patient-related outcomes? Ann Nutr Metab (2013) 0.91
Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency. Respir Res (2009) 0.91
Spirometry in chronic obstructive pulmonary disease. BMJ (2006) 0.90
Reported and unreported exacerbations of COPD: analysis by diary cards. Chest (2007) 0.90
Tumor necrosis factor-{alpha} rs361525 polymorphism is associated with increased local production and downstream inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2010) 0.90
Polyclonal free light chains: a biomarker of inflammatory disease or treatment target? F1000 Med Rep (2013) 0.90
Exacerbations of COPD diagnosed in primary care: changes in spirometry and relationship to symptoms. COPD (2005) 0.89
Multistudy fine mapping of chromosome 2q identifies XRCC5 as a chronic obstructive pulmonary disease susceptibility gene. Am J Respir Crit Care Med (2010) 0.89
Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency. Respir Res (2012) 0.88
Myeloid related protein-8/14 stimulates interleukin-8 production in airway epithelial cells. Am J Respir Cell Mol Biol (2003) 0.88
Alpha one antitrypsin deficiency: from gene to treatment. Respiration (2007) 0.87
The relationship of chronic sputum expectoration to physiologic, radiologic, and health status characteristics in alpha(1)-antitrypsin deficiency (PiZ). Chest (2002) 0.87
The effect of posture on asynchronous chest wall movement in COPD. J Appl Physiol (1985) (2013) 0.86
The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD. Respir Med (2006) 0.86
Identifying COPD patients at increased risk of mortality: predictive value of clinical study baseline data. Respir Med (2008) 0.86
Outdoor air pollution is associated with rapid decline of lung function in alpha-1-antitrypsin deficiency. Occup Environ Med (2010) 0.86
Aα-Val360: a marker of neutrophil elastase and COPD disease activity. Eur Respir J (2012) 0.86
Cardiovascular and musculskeletal co-morbidities in patients with alpha 1 antitrypsin deficiency. Respir Res (2010) 0.86
Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc (2015) 0.85
Pathological networking: a new approach to understanding COPD. Thorax (2007) 0.85
CT scan appearance, densitometry, and health status in protease inhibitor SZ alpha1-antitrypsin deficiency. Chest (2009) 0.84
Effect of expectoration on inflammation in induced sputum in alpha-1-antitrypsin deficiency. Respir Med (2005) 0.84
TargetCOPD: a pragmatic randomised controlled trial of targeted case finding for COPD versus routine practice in primary care: protocol. BMC Pulm Med (2014) 0.83
Modification of gene expression and increase in alpha1-antitrypsin (alpha1-AT) secretion after homologous recombination in alpha1-AT-deficient monocytes. Hum Gene Ther (2007) 0.83
Randomised controlled trial for emphysema with a selective agonist of the γ-type retinoic acid receptor. Eur Respir J (2012) 0.83
A study to assess COPD Symptom-based Management and to Optimise treatment Strategy in Japan (COSMOS-J) based on GOLD 2011. Int J Chron Obstruct Pulmon Dis (2013) 0.83